0001640334-21-001775.txt : 20210908 0001640334-21-001775.hdr.sgml : 20210908 20210805145606 ACCESSION NUMBER: 0001640334-21-001775 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Skye Bioscience, Inc. CENTRAL INDEX KEY: 0001516551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 450692882 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 5910 PACIFIC CENTER BLVD, SUITE 320 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (949) 480-9051 MAIL ADDRESS: STREET 1: 5910 PACIFIC CENTER BLVD, SUITE 320 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Emerald Bioscience, Inc. DATE OF NAME CHANGE: 20190325 FORMER COMPANY: FORMER CONFORMED NAME: Nemus Bioscience, Inc. DATE OF NAME CHANGE: 20141030 FORMER COMPANY: FORMER CONFORMED NAME: LOAD GUARD LOGISTICS, INC. DATE OF NAME CHANGE: 20121107 CORRESP 1 filename1.htm skye_corresp.htm

SKYE BIOSCIENCE, INC.

5910 Pacific Center Boulevard

Suite 320

San Diego, CA 92121

 

August 5, 2021

 

SUBMISSION VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

 

Attn:

Ms. Lauren Hamill

 

 

Re:

Skye Bioscience, Inc.

 

 

Registration Statement on Form S-3

 

 

Filed July 29, 2021

 

 

File No. 333-258243

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Skye Bioscience, Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement to August 9, 2021, 4:00 p.m., Eastern Time, or as soon thereafter as is reasonably practicable.

 

Thank you for your assistance in processing this filing. Should you have any questions or comments regarding this matter, please do not hesitate to contact the Company’s counsel, Mr. Mark C. Lee at (916) 442-1111.

 

 

Sincerely,

 

 

 

/s/ Punit Dhillon

 

Punit Dhillon,

 

Chief Executive Officer

 

cc:

Mark C. Lee, Esq., Greenberg Traurig, LLP